NCT01080820View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Healthy
Interventions
DRUG

CMX157

One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.

DRUG

Placebo

One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.

DRUG

Viread

One single oral dose of 300mg Viread.

Trial Locations (1)

53704

Covance, Madison

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY